Ozempic helps Type 1 diabetes patients quit insulin treatments in small study
Ozempic helps Type 1 diabetes patients quit insulin treatments in small study
Ozempic: A Breakthrough Treatment for Type 1 Diabetes?
Have you heard of Ozempic? This blockbuster drug has gained popularity as a weight-loss aid. However, a recent study has uncovered another potential use for it: helping individuals newly diagnosed with type 1 diabetes reduce or eliminate the need for daily insulin shots. While these findings are based on a small study of ten patients and further research is needed, they open up a new realm of possibilities for the treatment of type 1 diabetes.
Type 1 diabetes is a condition where the immune system mistakenly attacks the pancreatic cells responsible for producing insulin. Insulin is crucial for moving sugars from food into the body’s cells to be used as fuel. As a result, individuals with type 1 diabetes must rely on synthetic insulin through daily injections or an attached pump to survive.
Unlike type 2 diabetes, which is often associated with obesity and can be managed with lifestyle changes and medications, type 1 diabetes requires lifelong insulin therapy. However, researchers have been exploring whether newer type 2 diabetes drugs, such as Ozempic, could help manage type 1 diabetes when combined with insulin.
The latest study, published in the New England Journal of Medicine, reveals an intriguing possibility. Researchers wanted to determine if Ozempic, or more specifically, its active ingredient semaglutide, could replace insulin in individuals recently diagnosed with type 1 diabetes, at least temporarily.
The study included ten patients aged between 21 and 39, who were within three months of their type 1 diabetes diagnosis. Initially, they were given a low dose of semaglutide through weekly injections to ensure their blood sugar did not drop dangerously low. Over time, the semaglutide dose was increased while mealtime insulin doses were decreased.
- Scientists have successfully grown human kidneys inside pigs for th...
- Why Football Players Prefer Lower Jersey Numbers
- Bruce Springsteen postpones shows due to peptic ulcers.
Remarkably, within three months, all ten patients were able to stop their mealtime insulin, and seven of them also stopped their long-acting overnight insulin within six months. These positive outcomes persisted throughout the one-year follow-up period, with the patients’ average A1C levels (a measure of long-term blood sugar control) below 6%. This level falls within the target range for people with type 1 diabetes.
While experts not involved in the study find these results promising, they emphasize the need for more extensive research. Nevertheless, this study highlights the potential for extending the “honeymoon period,” the time when newly diagnosed individuals with type 1 diabetes still have a reserve of functioning beta cells.
Semaglutide works by aiding beta cells in producing more insulin when blood sugar levels are high, preventing the liver from releasing excessive sugar, and slowing digestion. If semaglutide can help newly diagnosed type 1 diabetes patients sustain their beta cell functioning and reduce their reliance on insulin injections, it could significantly improve their quality of life. Weekly injections offer practical advantages over multiple daily injections, simplifying treatment routines.
Furthermore, managing blood sugar levels becomes challenging when trying to match insulin doses with food intake, resulting in fluctuating levels. By minimizing these swings over an extended period, the risk of diabetes complications like nerve damage, eye problems, kidney disease, and heart disease could potentially be reduced.
While the possibility of Ozempic replacing insulin for an extended period is exciting, it is worth considering the long-term implications for patients’ beta cell functioning. Researchers will need to explore the effects and safety of semaglutide in larger and longer-term studies to determine its viability as an alternative or adjunct treatment for type 1 diabetes.
In conclusion, the potential benefits of Ozempic and semaglutide in the management of type 1 diabetes offer hope for individuals diagnosed with this condition. Although more research is needed, these preliminary findings pave the way for innovative approaches to managing type 1 diabetes, ultimately improving the lives of those affected by this chronic condition.
### QUESTION Diabetes is defined best as…See Answer
“Overall, these are promising early results, suggesting it may be possible to extend the honeymoon period in early type 1 diabetes,” said Josh Vieth, director of research for JDRF, a nonprofit organization dedicated to funding type 1 diabetes research.
Dr. Mary-Elizabeth Patti, the director of the hypoglycemia clinic at Joslin Diabetes Center in Boston, also commented on the study’s findings. While semaglutide has already demonstrated improvements in blood sugar control for individuals with long-established type 1 diabetes when combined with insulin, the study raises the intriguing possibility of the drug assisting newly diagnosed patients. Semaglutide may combat “glucotoxicity,” where chronic high blood sugar further impairs the functioning of the remaining beta cells.
However, all three experts stress the need for further research. One potential concern is whether semaglutide may increase stress on beta cells in the long run, affecting their functioning and overall viability.
In conclusion, if semaglutide can replace or minimize the need for insulin injections in the early stages of type 1 diabetes, it would significantly enhance the quality of life for individuals living with this condition. Additionally, preventing drastic blood sugar fluctuations could potentially reduce the risk of complications associated with diabetes. The study’s findings open up exciting possibilities for the future of type 1 diabetes management, and ongoing research will continue to shed light on the potential benefits and risks of incorporating semaglutide into treatment regimens.
More information on GLP-1 medications and type 1 diabetes can be found on the JDRF website.
Sources:
– Paresh Dandona, MD, professor of medicine, Jacobs School of Medicine and Biological Sciences, State University of New York at Buffalo, Williamsville, N.Y.
– Mary-Elizabeth Patti, MD, director of the hypoglycemia clinic, Joslin Diabetes Center, associate professor of medicine, Harvard Medical School, Boston
– Josh Vieth, PhD, director of research, JDRF International, New York City
– New England Journal of Medicine, Sept. 7, 2023
